CANBIND Study Ad.jpgOur biomarker study (CAN-BIND) offers individuals with depression
(18-65 years) treatment with a widely available anti-depressant (not a
trial drug). The aim is to identify biological indicators of treatment
response so that sometime in the future, we might be able to figure out
early what medications are more likely to work for a particular person,
make better treatment decisions. Since the study involves a lot of
participant time for interviews, blood work, MRI scans, EEG, etc., there
compensation – up to $400 per patient who completes the full study.